Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
Network meta-analysis finds similar overall survival for three HCC regimens
Three drugs show similar survival for unresectable liver cancer patients
A network meta-analysis of 11 studies in unresectable hepatocellular carcinoma found no statistically significant differences in overall sur…
Three drugs show similar survival for unresectable liver cancer patients, offering patients clearer choices without proving one option is de…
Combination immunotherapy and targeted therapy regimens show favorable survival outcomes versus monotherapies in unresectable hepatocellular carcinoma
New Data Reveals Which Liver Cancer Treatments Work Best Over Time
This systematic review and pooled analysis of parametric survival curves from 15 randomized controlled trials evaluated first-line treatment…
This research shows that combining two different cancer drugs helps patients live longer than using just one, but the benefit isn't constant…
HBV-positive status linked to higher surgical conversion in unresectable HCC receiving triple therapy
HBV-positive linked to better outcomes in liver cancer triple therapy
This single-center retrospective cohort study evaluated triple therapy with TACE, lenvatinib, and PD-1 inhibitors in 190 patients with initi…
In unresectable liver cancer, triple therapy with TACE, lenvatinib, and PD-1 inhibitors worked better in HBV-positive patients, a small retr…
Triple therapy with TACE, TKIs, and ICIs shows survival benefits in unresectable hepatocellular carcinoma
Triple therapy offers a 52% chance of living three years with advanced liver cancer
This retrospective cohort study evaluated 270 patients with unresectable hepatocellular carcinoma receiving first-line triple therapy across…
Patients with advanced liver cancer receiving triple therapy had a 52% chance of surviving three years, offering new hope for those facing d…
TACE plus donafenib and camrelizumab shows improved outcomes in unresectable hepatocellular carcinoma
Liver Cancer Patients May Live Twice as Long With New Combo
This single-center retrospective cohort study compared TACE plus donafenib and camrelizumab to TACE plus donafenib alone in 116 patients wit…
A new combination therapy could nearly double survival time for advanced liver cancer patients.
TACE plus camrelizumab and rivoceranib prolongs progression-free survival versus TACE alone in unresectable HCC
Combination therapy extends time without cancer progression in liver cancer patients
This phase II randomized trial in 200 patients with unresectable hepatocellular carcinoma compared TACE plus camrelizumab and rivoceranib (T…
Adding two new drugs to standard liver cancer treatment helped patients go 10.8 months longer without their cancer getting worse compared to…
Research across Hepatocellular Carcinoma
Related studies from across the Hepatocellular Carcinoma family.
Specific natural products modulate the NRF2-ferroptosis axis in preclinical models of hepatocellular carcinoma
Natural products may help treat liver cancer and injury
This mini-review synthesizes evidence from preclinical models regarding the role of natural products in modulating the NRF2-ferroptosis axis…
Certain natural compounds show promise in protecting the liver and making liver cancer cells more sensitive to treatment in early research.
AKR1B10 may serve as a serum biomarker for AFP-negative hepatoblastoma subtypes
Scientists Explore Blood Marker Idea for Childhood Liver Cancer
This narrative review explores the potential of Aldo-keto reductase 1B10 (AKR1B10) as a biomarker for pediatric liver tumors. The authors su…
A new review suggests a protein called AKR1B10 might one day help spot some childhood liver cancers, but no patient data exist yet.
Surgical resection plus postoperative TACE yields recurrence-free status in rare primary clear cell liver carcinoma
Rare Liver Cancer Case Treated With Surgery and TACE
This is a case report and literature review describing a 74-year-old woman with hepatitis B-related cirrhosis and primary clear cell carcino…
A 74-year-old woman with a rare liver cancer stayed cancer-free for years after surgery plus targeted chemotherapy delivered into the liver.
cGAS-STING pathway serves as a central axis for innate immune activation in MASLD and HCC
New research identifies a key immune pathway in fatty liver disease
This systematic review explores the role of the cGAS-STING pathway in metabolic dysfunction-associated steatotic liver disease and hepatocel…
A specific immune pathway called cGAS-STING may play a major role in how fatty liver disease progresses and leads to serious complications.
18F-FDG PET/CT SUVmax and TLR are associated with increased microvascular invasion risk in HCC
PET Imaging Biomarkers Help Predict Liver Cancer Risks
This meta-analysis of 2,023 patients evaluates 18F-FDG PET/CT imaging biomarkers for predicting microvascular invasion in hepatocellular car…
New analysis shows specific PET imaging markers can help doctors predict microvascular invasion in patients with hepatocellular carcinoma.
15 germline loci associated with hepatocellular carcinoma identified across multiple ancestries
Genetic Variants Linked to Risk of Liver Cancer Identified
This meta-analysis identifies 15 genome-wide significant germline loci associated with hepatocellular carcinoma across diverse ancestries. T…
Researchers identified 15 genetic locations linked to liver cancer, including some that act independently of liver scarring and vary by ance…
Pembrolizumab, regorafenib, and cabozantinib improve overall survival in advanced hepatocellular carcinoma after prior therapies
New data compares treatments for advanced liver cancer patients
This network meta-analysis evaluates regorafenib, cabozantinib, pembrolizumab, and ramucirumab for advanced hepatocellular carcinoma (HCC) f…
New research compares several drugs for advanced liver cancer, finding that some treatments offer better survival and safety for patients.
HAIC combined with TKI and PD-1 inhibitor improves overall survival in unresectable hepatocellular carcinoma
Triple therapy improves survival for patients with liver cancer
This meta-analysis of 2,386 patients with unresectable hepatocellular carcinoma found that HAIC combined with a TKI and a PD-1 inhibitor sig…
Adding a specific chemotherapy infusion to a combination of two drugs may help patients with advanced liver cancer live longer.
Degradable Starch Microspheres TACE shows no significant improvement in survival for hepatocellular carcinoma
DSM-TACE Shows Comparable Results to Conventional Liver Cancer Treatments
This meta-analysis of 6 studies evaluated degradable Starch Microspheres TACE (DSM-TACE) compared to conventional treatments for hepatocellu…
A new type of liver cancer treatment shows similar tumor response and survival rates compared to standard care methods.
Broader liver transplant eligibility criteria show no difference in survival outcomes for hepatocellular carcinoma
Different Liver Transplant Rules Show Similar Survival for Cancer Patients
This post-hoc analysis of 485 patients with hepatocellular carcinoma found no statistically significant differences in overall survival, rec…
New analysis shows that several different sets of rules for liver transplants result in similar survival rates for patients with liver cance…
Conversion therapy yields 25.4% pooled resection rate in unresectable HCC across 34 studies
Conversion therapy helps some patients with liver cancer surgery
This meta-analysis of 34 studies (5,137 patients) estimates a 25.40% pooled resection rate after conversion therapy in initially unresectabl…
New data shows that conversion therapy helps about 25% of patients with unresectable liver cancer become eligible for surgery.
RTK-RAS pathway alterations are more frequent in cholangiocarcinoma than in hepatocellular carcinoma
Genetic markers help distinguish between different types of liver and bile duct cancers
This meta-analysis of genomic and single-cell transcriptomic data identifies a higher burden of RTK-RAS alterations in cholangiocarcinoma co…
New research identifies specific genetic signals that help doctors tell the difference between two similar types of liver cancer.
Questions about Unresectable Hepatocellular Carcinoma
Does adding camrelizumab improve outcomes for unresectable hepatocellular carcinoma patients?
Adding camrelizumab to standard treatments like TACE and targeted drugs significantly improves tumor response, disease control, and survival times for patients with unresectable hepatocellular carcinoma.
Full answer →Can triple therapy help patients with unresectable hepatocellular carcinoma live longer?
Yes, triple therapy (TACE plus targeted drugs and immunotherapy) can help patients with unresectable hepatocellular carcinoma live longer, with studies showing improved overall survival and progression-free survival compared to TACE alone or double therapy.
Full answer →Does having HBV make surgery more likely for unresectable hepatocellular carcinoma?
Having hepatitis B virus (HBV) infection is linked to a higher chance of surgical conversion for patients with unresectable hepatocellular carcinoma treated with triple therapy.
Full answer →